SIRPA and lung adenocarcinoma: Patients with higher expression of SIRPα had worse disease‐free survival (DFS) and overall survival (OS) in lung squamous cell carcinoma (LUSC), but SIRPα had no predictive value in lung adenocarcinoma (LUAD, Figure S6a,b).